Optimization of ultra fast nDIA proteomics approach
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: 
Yun Xiong
LAB HEAD: Philip L. Lorenzi
PROVIDER: PXD055919 | Pride | 2026-01-14
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| 050424_Hela200ng_AGC100_1.raw | Raw | |||
| 050424_Hela200ng_AGC100_2.raw | Raw | |||
| 050424_Hela200ng_AGC100_3.raw | Raw | |||
| 050424_Hela200ng_AGC200_1.raw | Raw | |||
| 050424_Hela200ng_AGC200_2.raw | Raw |
Items per page: 5 1 - 5 of 132 |
Similar Datasets
Project description:DNA interstrand crosslinks (ICLs) are highly cytotoxic lesions that block essential cellular processes like replication and transcription. Endogenous ICLs can be induced by reactive aldehydes produced during normal cellular metabolism. Defective repair of these aldehyde-induced ICLs is associated with Fanconi anemia (FA), a cancer predisposition syndrome. We previously showed that acetaldehyde-induced ICLs are repaired by the FA-pathway and a novel excision-independent pathway. Here, we demonstrate that ICLs induced by acrolein, another cellular aldehyde, are also repaired by both pathways, establishing the generality of aldehyde ICL repair. Focusing on the FA pathway, we identify DNA polymerase kappa (Polκ) as the primary translesion synthesis (TLS) polymerase responsible for the insertion step during lesion bypass of unhooked aldehyde ICLs. This function requires Polκ's catalytic activity and PCNA interaction domains but is independent of Rev1 interaction. In contrast, Polκ has a minor non-catalytic role in the extension step of cisplatin ICL repair that is dependent on Rev1 interaction. Our work reveals a key role for Polκ in aldehyde ICL repair and provides mechanistic insights into how different ICL structures determine the choice of TLS polymerases during repair.
2025-09-29 | PXD066315 | Pride
Project description:Using nanoparticles based plasma enrichment strategies on plasma samples, we were able to achieve a huge increase of identified plasma proteins from around 700 to more than 5000 proteins as compared to neat plasma digest. The substantial increase in depth allowed us to perform in-depth analysis and we were able to apply this to a small cohort of plasma samples from pancreatic cancer (PC) patients with primary tumor, tumor that had metastases vs healthy controls. Majority of identified proteins were part of the Human Plasma Proteome Project (HPPP) database, and more than 300 proteins are on the list of FDA approved drug targets. We showed a large and significant increase in ribosomal proteins in plasma of PC that metastasized. ADH1C and ADH1B, both members of the alcohol dehydrogenase family, had one of the largest increase and potentially correlated with liver metastasis. We further highlighted 15 different potentially secreted and/or cell surface proteins that were otherwise not identified in neat, digested plasma and have potential to be useful markers due to their cancer associations. Lastly, we compared different mass spectrometer (Orbitrap Astral and Orbitrap Ascend) and column (depth and throughput) setups on the same dataset and showed similar conclusions potentially can be achieved, although the depth approach on the newer instrumentations can reveal additional insights in the plasma proteome.
2025-12-03 | PXD065103 | Pride
Project description:Synthetic lethal interactions (SLIs) based on genomic alterations in cancer have been therapeutically explored. We investigated the SLI space as a function of differential RNA expression in cancer and normal tissue. Computational analyses of functional genomic and gene expression resources uncovered a cancer-specific SLI between the paralogs cytidine diphosphate diacylglycerol synthase 1 (CDS1) and CDS2. The essentiality of CDS2 for cell survival is observed for mesenchymal-like cancers, which express low levels of CDS1 and account for roughly half of all cancers. We confirm the CDS1-2 SLI in cultured cancer cell lines and tumor-bearing mice. Mechanistically, the CDS1-2 SLI is accompanied by disruption of lipid homeostasis, including accumulation of cholesterol esters and triglycerides, and apoptosis. Genome-wide CRISPR-Cas9 knockout screens in CDS1-negative cancer cells identify no common escape mechanism of death caused by CDS2 ablation, indicating the robustness of the SLI. Synthetic lethality is driven by CDS2 dosage and depends on catalytic activity. Thus, CDS2 may serve as a pharmacologically tractable target in mesenchymal-like cancers.
2025-03-31 | PXD045833 | Pride
Project description:The adaptive responses to oxygen depletion orchestrated by hypoxia-inducible factors (HIFs) produce profound effects on multiple pathways. A canonical metabolic response is enhanced fermentation, but this can generate an unfavorably acidic environment under poor capillary perfusion. It is unclear how cells balance the metabolic benefits of hypoxic responses against knock-on consequences on acid-base homeostasis. We studied the interplay between hypoxia and acidosis on HIF signaling in colorectal cancer cell lines that can survive acidic conditions. Hypoxia stabilized HIF-1α, but this effect was transient in combination with acidosis. By 48 h, HIF-1α induction decreased in proportion to acidification. Proteomic analyses identified responses that followed HIF-1α, including canonical HIF targets (CA9, PDK1), but these did not reflect a proteome-wide downregulation. Responses to acidosis and hypoxia were enriched in lysosomal proteins, but not proteasomal components, implicating the former degradation pathway in transient HIF-1α activation under acidosis. Moreover, HIF-1α decay was not due to decreased HIF1A transcription but was blocked by lysosomal inactivation (bafilomycin-A1). Acidotic hypoxia increased the abundance of lysosomes and activated autophagy by disabling the inhibitory influence of mammalian target of rapamycin complex 1, resulting in HIF-1α degradation. By blocking HIF-driven fermentative upregulation, this mechanism protects the cellular environment from deleterious acid-overloading, an outcome that outweighs the biosynthetic benefits of raised glycolytic flux under suppressed respiration. Thus, alkaline conditions are permissive for at least some aspects of HIF-1α signaling, but may not reflect tumor microenvironment chemistry. Consequently, acidic hypoxic tumor regions may not necessarily overlay with sites of HIF induction
2025-06-30 | PXD062474 | Pride
Project description:Determining the genomic localization of chromatin features is an essential aspect of investigating gene expression control, and ChIP-Seq has long been the gold standard technique for interrogating chromatin landscapes. Recently, the development of alternative methods, such as CUT&Tag, have provided researchers with alternative strategies that eliminate the need for chromatin purification, and allow for in situ investigation of histone modifications and chromatin bound factors. Mindful of technical differences, we set out to investigate whether distinct chromatin modifications were equally compatible with these different chromatin interrogation techniques. We found that ChIP-Seq and CUT&Tag performed similarly for modifications known to reside at gene regulatory regions, such as promoters and enhancers, but major differences were observed when we assessed enrichment over heterochromatin-associated loci. Unlike ChIP-Seq, CUT&Tag detects robust levels of H3K9me3 at a substantial number of repetitive elements, with especially high sensitivity over evolutionarily young retrotransposons. IAPEz-int elements for example, exhibited underrepresentation in mouse ChIP-Seq datasets but strong enrichment using CUT&Tag. Additionally, we identified several euchromatin-associated proteins that co-purify with repetitive loci and are similarly depleted when applying ChIP-based methods. This study reveals that our current knowledge of chromatin states across the heterochromatin portions of the mammalian genome is extensively incomplete, largely due to36 limitations of ChIP-Seq. We also demonstrate that newer in situ chromatin fragmentation-based techniques, such as CUT&Tag and CUT&RUN, are more suitable for studying chromatin modifications over repetitive elements and retrotransposons.
2025-08-26 | PXD067760 | Pride
Project description:Acute pancreatitis (AP), a severe inflammatory disorder of the pancreas, lacks effective pharmacological treatment. The disease is primarily driven by necrosis of pancreatic acinar cells (PACs), which intensifies inflammation and organ injury. This study explores the potential of BCL2 inhibitors, specifically Navitoclax and Venetoclax, to shift cell death pathways from necrosis to apoptosis and thereby mitigate disease severity. Ex vivo models using cerulein or ethanol/palmitoleic acid (EtOH/POA) showed that both inhibitors significantly reduced necrosis, increased apoptosis, and improved PAC viability and ATP levels. In mouse models of AP, both drugs promoted apoptosis and decreased tissue necrosis, with Venetoclax showing superior efficacy and safety. Venetoclax markedly reduced disease severity in two AP models without affecting healthy tissue or inducing thrombocytopenia. In contrast, Navitoclax caused apoptosis even in healthy tissue and triggered thrombocytopenia. Importantly, both drugs attenuated pathological Ca2+ responses in PACs and upregulated the expression of Ca²⁺-binding proteins S100A8/A9 and the chemokine CCL8. The latter may mediate enhanced apoptotic clearance and limit secondary necrosis, supporting the therapeutic shift from necrosis to apoptosis. Proteomic analyses revealed extensive drug-induced remodeling. In the short-term AP model, both inhibitors altered expression of proteins linked to intracellular compartments and extracellular signaling, reflecting cellular adaptation. In CP, Navitoclax strongly upregulated ECM and lysosomal proteins while downregulating ribosomal components – indicating intensified fibrosis and suppressed protein synthesis. Venetoclax had milder effects and did not worsen fibrosis. Despite Navitoclax’s efficacy toward activated pancreatic stellate cells in vitro, it exacerbated fibrosis and tissue atrophy in CP in vivo, likely due to ongoing parenchymal damage and stellate cell activation. Together, these findings demonstrate that selective BCL2 inhibition with Venetoclax promotes apoptosis, reduces necrosis, and improves outcomes in AP, supporting its repurposing as a therapeutic strategy. However, BCL2 inhibition does not benefit CP and may aggravate fibrosis, underscoring the need for context-specific approaches.
2025-08-04 | PXD064881 | Pride
Project description:Signals from the microenvironment are known to be critical for development, sustaining adult stem cells, and for oncogenic progression. While candidate niche-driven signals that can promote cancer progression have been identified, concerted efforts to comprehensively map microenvironmental ligands for cancer stem cell specific surface receptors have been lacking. Here, we use temporal single cell RNA-sequencing to identify molecular cues from the bone marrow stromal niche that engage leukemia stem cells (LSC) during oncogenic progression. We integrate these data with our RNA-seq analysis of human LSCs from distinct aggressive myeloid cancer subtypes and our CRISPR based in vivo LSC dependency map7 to develop a temporal receptor-ligand interactome essential for disease progression. These analyses identify the taurine transporter (TauT)-taurine axis as a critical dependency of myeloid malignancies. We show that taurine production is restricted to the osteolineage population during cancer initiation and expansion. Inhibiting taurine synthesis in osteolineage cells impairs LSC growth in vitro and improves survival outcomes in vivo. Using TauT genetic loss of function murine models and patient-derived AML cells, we show that TauT inhibition significantly impairs in vivo myeloid leukemia progression. Consistent with elevated TauT expression in venetoclax resistant AML, TauT inhibition synergizes with venetoclax to block growth of primary human AML cells. Mechanistically, our metabolomic, proteomic and transcriptomic approaches indicate that loss of taurine uptake inhibits Rag-GTP dependent mTOR activation and downstream glycolytic metabolism. Collectively, our work establishes the temporal landscape of stromal signals during leukemia progression and identifies taurine as an important regulator of myeloid malignancies.
2025-03-28 | PXD062322 | Pride
Project description:Integrator (INT) is a metazoan-specific complex that targets promoter-proximally paused RNA polymerase II (RNAPII) for termination, preventing immature RNAPII from entering gene bodies and functionally attenuating transcription of stress-responsive genes. Mutations in INT subunits are associated with many human diseases, including cancer, ciliopathies and neurodevelopmental disorders, but how reduced INT activity contributes to disease is unknown. Here, we demonstrate that loss of INT-mediated termination in human cells triggers the integrated stress response (ISR). INT-depletion causes upregulation of short genes such as the ISR transcription factor ATF3. Further, immature RNAPII that escapes into genes upon INT-depletion is prone to premature termination, generating incomplete pre-mRNAs with retained introns. Retroelements within retained introns form double-stranded RNA (dsRNA) that is recognized by Protein Kinase R (PKR), which drives ATF4 activation and prolonged ISR. Critically, patient cells with INT mutations exhibit dsRNA accumulation and ISR activation, thereby implicating chronic ISR in diseases caused by INT-deficiency.
2026-01-08 | PXD060648 | Pride
Project description:Background and Aims: Signet-Ring (SR) cell carcinoma (SRCC) is an increasingly prevalent form of gastric cancer, known for its late presentation and poor treatment outcomes. Using our spatial proteomics pipeline, Deep Visual Proteomics (DVP), we aimed to comprehensively explore the SRCC proteome landscape in a single patient to uncover unknown disease mechanisms that could be individually targeted for therapeutic purposes. Methods: We applied DVP, which combines image-based artificial intelligence with automated microdissection and ultra-high sensitivity mass spectrometry, to SR cell-positive tissues from the bladder, seminal vesicle, lymph node, and prostate within a single patient. Results: DVP allowed us to perform in-depth spatial proteome analysis of SRCC presenting in different organs of a single patient. We identified alternations in DNA damage response (DDR) pathways, particularly in the pathways associated with ataxia-telangiectasia mutant (ATR) and DNA mismatch repair (MMR), suggesting replication stress as the leading factor of SRCC mutagenicity. Additionally, we identified an enrichment of immune-related proteins and could observe infiltration of cytotoxic T lymphocytes. Conclusion: Analyzing the SRCC proteome across different organs within a single patient allowed us to confirm known disease patterns and identify novel biological mechanisms contributing to SRCC aggressiveness. Our data provided insights into why chemotherapy was unsuccessful and explained the significant life extension and improved quality of life following PD-1 inhibitor treatment, which led to tumor stasis.
2025-05-07 | PXD053079 | Pride
Project description:Splicing factors control exon inclusion in messenger RNA, shaping transcriptome and proteome diversity. Their catalytic activity is regulated by multiple layers, making single-omic measurements on their own fall short in identifying which splicing factors underlie a phenotype. Here, we propose that splicing factor activity can be estimated by interpreting changes in exon inclusion. To see if this is the case we benchmarked methods to construct splicing factor→exon networks and calculate splicing factor activity. Combining RNA-seq perturbation-based networks with VIPER (virtual inference of protein activity by enriched regulon analysis) accurately captures splicing factor activation modulated by different regulatory layers. This approach consolidates splicing factor regulation into a single score derived solely from exon inclusion signatures, allowing functional interpretation of heterogeneous conditions. As a proof of concept, we identify recurrent cancer splicing programs, revealing oncogenic- and tumor suppressor-like splicing factors missed by conventional methods. These programs correlate with patient survival and key cancer hallmarks: initiation, proliferation, and immune evasion. Altogether, we show splicing factor activity can be accurately estimated from exon inclusion changes, enabling comprehensive analyses of splicing regulation with minimal data requirements. In this dataset, we share our results from analyzing the BJ fibroblast-based model for carcinogenesis through proteomics and phosphoproteomics.
2025-07-27 | PXD066623 | Pride